Funding for this research was provided by:
Associazione Italiana per la Ricerca sul Cancro (MFAG 18880)
Breast Cancer Research Foundation (BCRF-18-037)
Text and Data Mining valid from 2019-05-29
First Online: 29 May 2019
Ethics approval and consent to participate
: Not pertinent. The original study (TREnd trial) from which the data presented here was derived was approved by the competent ethics committees.
: Not pertinent.
: GC has received research funding from Pfizer, Roche, Novartis, Sanofi, Celgene, Servier, Orion, AstraZeneca, Seattle Genetics, AbbVie, Tesaro, BMS, Merck-Serono, Medivation, Medimmune and Bayer, and has had consulting/advisory role from Roche, Seattle Genetics, Novartis, Lilly, Pfizer, Foundation Medicine, Nanostring, Samsung and Mylan. SC has had consulting role for Lilly. GA has received research funding from Novartis, and has had a consulting/advisory role with Pfizer, Novartis and Lilly. LBi has received research funding from Celgene, Genomic Health and Novartis, and has had a consulting/advisory role with AstraZeneca, Celgene, Eisai, Genomic Health, Ipsen, Lilly, Novartis, Pfizer, Pierre Fabre and Roche. ADL has received research funding from AstraZeneca, Pfizer and Pierre-Fabre, and has had a consulting/advisory role with AstraZeneca, Bayer, Celgene, Daichi-Sankyo, Eisai, Genomic Health, Ipsen, Lilly, Novartis, Pierre-Fabre, Pfizer and Roche. LM has received research funding from Pfizer and has had consulting/advisory role for Pfizer and Novartis. All other authors have nothing to disclose.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.